Olympus, Boston Scientific & more — 3 GI company key notes

Here are three updates on gastroenterology and endoscopy companies.

Advertisement

Paris, France-based Nanobiotix reported the results of its phase I/II clinical trial for NBTXR3, its liver cancer drug.

Three senior Olympus executives utilized their right to invoke the Fifth Amendment during questioning over internal company emails.

Following news about superbug outbreaks at numerous facilities, providers and hospitals are trying out disposable scopes, such as Boston Scientific’s single-use bronchoscope.

More articles on gastroenterology and endoscopy:
Which lifestyle factors are associated with serrated colorectal polyps? 5 study insights
AGA critiques ABIM maintenance of certification announcement: 3 takeaways
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.